Por: RTTNews Health July 26, 2024
AstraZeneca (,) said the Food and Drug Administration's Oncologic Drugs Advisory Committee acknowledged that Imfinzi met the primary endpoint of event-free survival in the treatment of resectable non-small cell lung cancer based on the AEGEAN Phase III trial results with an overall tolerable safety profile. The discussion noted that while the contribution by phase of neoadjuvant and adjuvant components of the perioperative regimen could not... + full article
RTTNews USA Health August 08, 2024
Conduit Pharmaceuticals () has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor. AstraZeneca will grant Conduit an exclusive license to both AZD1656... + más
Florida redfish contaminated with drugs. Study finds opioids, psychoactive medications and more. | Orlando Sentinel
First epinephrine nasal spray clears key FDA hurdle, promising needle-free alternative | CBS News
ABC7 USA Health October 24, 2023
is reviewing an application for the nasal spray vaccine FluMist to be able to be self-administered at home, drugmaker AstraZeneca said Tuesday.The vaccine, the only nasal spray option against flu, has been on the market in the United States since 2003. AstraZeneca has asked the... + más
When is the best time to get a flu shot? And what kind should I get? | Los Angeles Times
Flu shot myths make us sick — experts bust 6 of the major ones | New York Post
The Boston Globe USA Business June 14, 2023
ENERGYAstraZeneca signs deal with Waltham-based firm for renewable natural gasVanguard Renewables has signed a contract with drug giant AstraZeneca to deliver renewable natural gas to all of AstraZeneca’s 12 sites in the United States. Waltham-based Vanguard is developing... + más
High school scores and top performers from Friday, March 24 | Orlando Sentinel
High school scores and top performers from Thursday, March 9 | Orlando Sentinel
CBS News USA Politics April 28, 2023
A replacement for a key COVID-19 antibody drug that has been used to protect immunocompromised Americans could be available within months, executives for drugmaker AstraZeneca said Thursday, after promising early results suggested it may work against all known variants of... + más
FDA withdraws emergency use authorization of COVID drug because it is unlikely to be effective against new variants | ABC News
FDA pulls authorization for AstraZeneca’s Covid antibody drug Evusheld | NBC News
RTTNews USA Health April 27, 2023
AstraZeneca PLC (,) reported that its first quarter profit before tax increased to $2.26 billion from $553 million, last year. Earnings per share was $1.16 compared to $0.25. Core operating profit was $3.95 billion, an increase of 4% at CER. Core operating margin was 36%, up one... + más
AstraZeneca signs deal with Waltham-based firm for renewable natural gas | The Boston Globe
AstraZeneca says new COVID drug could guard against all variants of concern to date | CBS News
CNBC USA Business February 09, 2023
AstraZeneca has blockbuster projects in development that are set to make billions of dollars, according to its CFO.BSIP / Contributor / Getty ImagesDemand for Covid-19 vaccines has dropped as the pandemic enters its fourth year, but says it has blockbuster projects in... + más
Is the last 'Blockbuster' still open? The truth about Netflix show location | Newsweek
Last Blockbuster store, located in Oregon, to host contest winner for exclusive movie and game night | Fox Business
NBC News USA Nation January 27, 2023
The Food and Drug Administration has withdrawn emergency use authorization for AstraZeneca’s Covid-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of omicron. The FDA had limited Evusheld’s use... + más
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variants | ABC7
About iurex | Privacy Policy | Disclaimer |